A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma
Verónica Rey(Centro de Investigación Biomédica en Red de Cáncer), René Rodrı́guez(Instituto de Investigación Sanitaria del Principado de Asturias)
Cited by 10
Related Papers
Loss of p53 Induces Tumorigenesis in p21-Deficient Mesenchymal Stem Cells
|Neoplasia|2009|104
Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45
|Cell Death and Differentiation|2008|39
The multikinase inhibitor EC‐70124 synergistically increased the antitumor activity of doxorubicin in sarcomas
|International Journal of Cancer|2018|16